MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register
About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 13 - per page Next page
Order by
PITDC: Novel compound for treatment of treatment of bacterial infections and/or renal cancer disease
Active ingredient for the treatment of bacterial infections and/or renal cancer diseases More
Dendritic cell (DC) generation and manipulation technology for the development of cancer vaccines and rheumatoid arthritis (RA) therapeutics; Cytoplasmic Transduction Peptide (CTP) technology
Dendritic cell (DC) generation and manipulation technology for the development of a cancer vaccine and rheumatoid arthritis (RA) therapeutics. Based on DC manipulating technology, Creagene is developing DC-based cancer vaccines against renal cell car More
Sensitive Antibody-based Assay for the Measurement of c-Met Concentration Shed in Bodily Fluids Useful in the Diagnosis and Prognosis of Cancer
Methods and assays which may be used to diagnose and follow the progression of cancers associated with c-Met expression More
Small Molecule Inhibitors of c-Met
Novel small molecule inhibitors of c-Met signaling; these small molecules selectively bind to c-Met and have an IC50 in the micromolar range. More
T-cell Receptor Recognizing Renal Cell Carcinoma
This T-cell receptor recognizes a number of human kidney tumors and is not limited to use in patients with specific MHC types. More
Agonist Epitopes for Renal Cell Carcinoma
Peptides and antigen epitopes specific for RCC for use in the diagnosis, vaccination, or adoptive infusion of antigen specific T cells to treat patients with metastatic RCC More
Epoxy-guaiane Cancer Inhibitors: New Class of Natural Products Isolated from the African Plant Phyllanthus englerii
These englerins and their derivatives exhibit selective and potent renal cell inhibitory activity in vitro. More
Identification of a Novel Folliculin Interacting Protein, FNIP-1
Cloning and characterization of the first folliculin interacting protein FNIP-1 and purified antibodies that selectively bind to an epitope of FNIP-1 More
Biomarkers for Tissue Status
The invention relates to methods of quickly and accurately diagnosing renal cellular carcinoma (RCC) and monitoring renal tissue health as well as RCC treatment. More
Anti-Pax 2 Antibody
Anti-Pax 2 polyclonal antibodies that can be used for the detection of Pax-2 protein expression in a variety of kidney and neuronal tissues. More
Displaying 1..10 of 13 - per page Next page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us